Blogs & News

Monovet® 90 (monensin Type A medicated article) additional approvals

Global animal health company Huvepharma®, after receiving FDA approval in July 2019 for Monovet® 90, the first-available generic monensin in the United States, continues to expand the list of approved feed combinations with which Monovet can be fed. Following the company’s initial FDA combination approvals for use with Monovet 90 that were announced in mid-September, the FDA on October 11, 2019 has approved additional drug feed additive combinations with Monovet 90 in the manufacture of Type B and C medicated feeds.

This most recent round of FDA approvals expands the use of Monovet 90 to be fed in combination with other feed additives commonly used in receiving rations for feedlot cattle, including decoquinate for coccidiosis prevention and tilmicosin for respiratory disease therapy. For the list of all current medicated feed combinations approved with Monovet 90, please visit: www.monovet.us.

“We are very pleased about these additional combination approvals, and appreciate the positive responses received from cattle producers and feeders in the industry about the expanded choices. Huvepharma’s increasing product offerings brought to the livestock marketplace stems from years of dedicated effort put forth by our employees to provide our customers with relevant products that meet their needs,” says Glen Wilkinson, president of Huvepharma US.

Although Huvepharma has only been active in the US animal health market since 2005, the company began in Bulgaria over sixty years ago. Huvepharma operates three facilities that utilize biosynthesis (fermentation) to manufacture active substances, nutritional supplements, enzymes, probiotics, and ready medicinal formulations. The latest testament to the company’s commitment to animal health is the investment and construction of another state-of-the-art fermentation facility in Peshtera, Bulgaria which opened this September. This modern facility will not only increase Huvepharma’s overall production capacity by 30%, but ensures a consistent and ready supply of these products.

“Huvepharma’s newest production facility will allow us to meet the growing market demands for our broad line of fermented products both in the U.S. and internationally,” says Wilkinson. The company today ranks 10th among the largest veterinary pharmaceutical companies.

IMPORTANT SAFETY INFORMATION: MONOVET® 90 (monensin Type A medicated article): Not for Human Use. Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Consumption by unapproved species may result in toxic reactions and even fatalities. A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. When mixing and handling Monovet 90, use protective clothing, impervious gloves and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse with water. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.

About Huvepharma

Huvepharma is a privately owned global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. Huvepharma is headquartered in Sofia, Bulgaria with the U.S. headquarters located in Peachtree City, GA.

Huvepharma and Monovet are registered trademarks of Huvepharma EOOD.